BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32249632)

  • 1. Emerging therapies in β-thalassemia: toward a new era in management.
    Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
    Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
    Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Therapies in β-Thalassemia.
    Bou-Fakhredin R; Kuo KHM; Taher AT
    Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmet needs in β-thalassemia and the evolving treatment landscape.
    Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
    Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta Thalassemia: Monitoring and New Treatment Approaches.
    Khandros E; Kwiatkowski JL
    Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent trends in treatment of thalassemia.
    El-Beshlawy A; El-Ghamrawy M
    Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of beta thalassemia--a guide to molecular therapies.
    Thein SL
    Hematology Am Soc Hematol Educ Program; 2005; ():31-7. PubMed ID: 16304356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
    Cappellini MD; Porter JB; Viprakasit V; Taher AT
    Blood Rev; 2018 Jul; 32(4):300-311. PubMed ID: 29455932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
    Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
    Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
    Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
    Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insights Into Pathophysiology of β-Thalassemia.
    Sanchez-Villalobos M; Blanquer M; Moraleda JM; Salido EJ; Perez-Oliva AB
    Front Med (Lausanne); 2022; 9():880752. PubMed ID: 35492364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-thalassemia: is cure still a dream?
    Hodroj MH; Akiki N; Bou-Fakhredin R; Taher AT
    Minerva Med; 2023 Dec; 114(6):850-860. PubMed ID: 37534831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies in β-thalassaemia.
    Grech L; Borg K; Borg J
    Br J Clin Pharmacol; 2022 Jun; 88(6):2509-2524. PubMed ID: 34004015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
    Langer AL; Esrick EB
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and animal models for the investigation of β-thalassemia.
    Nai A; Cordero-Sanchez C; Tanzi E; Pagani A; Silvestri L; Di Modica SM
    Blood Cells Mol Dis; 2024 Jan; 104():102761. PubMed ID: 37271682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety in thalassemia: lessons from the present and directions for the future.
    Grech L; Sultana J; Borg K; Borg J
    Expert Opin Drug Saf; 2021 Aug; 20(8):937-947. PubMed ID: 33877003
    [No Abstract]   [Full Text] [Related]  

  • 17. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
    Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
    Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing.
    Corbacioglu S; Frangoul H; Locatelli F; Hobbs W; Walters M
    Am J Hematol; 2024 Mar; 99(3):422-429. PubMed ID: 38100154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2017 Clinical trials update in new treatments of β-thalassemia.
    Makis A; Hatzimichael E; Papassotiriou I; Voskaridou E
    Am J Hematol; 2016 Nov; 91(11):1135-1145. PubMed ID: 27502996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
    Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
    Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.